FIRST-IN-HUMAN (FIH)
First-in-Human (FIH) studies represent a critical milestone in the development of new therapies. CenExel provides the scientific expertise, operational excellence, and specialized infrastructure required to safely transition investigational treatments from preclinical research into human clinical trials. Our experienced teams support sponsors through every stage of early-phase development, delivering high-quality data and efficient study execution.
Studies Conducted
Acute & post-surgical pain focus
0
+
Trial Participants
Enrolled in acute pain studies
0
+
Active Sites
Specialized research locations
0
Overview
Leading First-in-Human Clinical Research
CenExel's First-in-Human research programs are designed to help sponsors evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of investigational therapies in humans for the first time. Our experienced investigators and research teams provide comprehensive support for early-phase clinical development across a wide range of therapeutic areas.
From protocol development and site activation to patient monitoring and data collection, we deliver reliable execution and scientific rigor that help sponsors make informed development decisions with confidence.
Conditions Covered
Acute First-in-Human Conditions We Research
Our acute First-in-Human research sites support a broad spectrum of post-operative and procedure-related pain conditions.
Central Nervous System (CNS)
Psychiatry & Behavioral Health
Pain & Inflammation
Metabolic Disorders
Rare Diseases
Immunology
Gastroenterology
Neurology
Cardiovascular Diseases
Respiratory Disorders
Our Approach
Why Sponsors Choose CenExEl for First-in-Human Studies
Our First-in-Human expertise extends beyond participant enrollment—we provide strategic scientific guidance, operational excellence, and high-quality data to support confident early-phase decision-making.
01
Early-Phase Expertise
Experienced investigators and scientific leaders support safe and efficient first-in-human study execution.
02
Advanced Clinical Pharmacology Capabilities
Comprehensive PK/PD assessments, biomarker analysis, and dose-escalation expertise.
03
Intensive Safety Monitoring
Dedicated medical oversight and real-time safety evaluations throughout study participation.
04
Rapid Study Start-Up
Streamlined site activation, participant recruitment, and operational processes designed to accelerate timelines.
Phase Coverage
Supported Trial Phases
We support early clinical development programs ranging from First-in-Human studies through Phase IV research, providing scientific expertise and operational excellence at every stage.
Active across all phases
Phase I
Phase II
Phase III
Phase IV
Our Phase I capabilities include single ascending dose (SAD), multiple ascending dose (MAD), food effect studies, drug-drug interaction studies, bioavailability assessments, biomarker-driven research, and proof-of-concept trials.
First-in-Human Task Force
CenExEl's First-in-Human Task Force brings together experienced investigators, clinical pharmacologists, and operational specialists dedicated to early-phase research excellence. The team supports complex study designs, adaptive protocols, dose-escalation strategies, and intensive safety monitoring to help sponsors confidently advance innovative therapies through critical development milestones.
Active Sites
15 Sites
CenExel Gaithersburg
CenExel Garden Grove
CenExel Atlanta
CenExel Marlton
CenExel Hollywood
Related Therapeutic Areas
Also in Pain & Inflammation
